XPENG
24.9.2021 08:00:17 CEST | Business Wire | Press release
HT Aero, an urban air mobility (UAM) company in which XPeng Inc. is an investor, today unveiled future urban usage scenarios for its fifth-generation flying vehicle XPeng X2 ("X2"), including autonomous flight take-off and landing for specific city scenarios, back-end scheduling, charging and flight control.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923006034/en/
XPeng X2 will present at the 13th Airshow China 2021, starting on September 28 in Zhuhai, Guangdong Province.
X2 is equipped with a robust, highly intelligent flight control system and superior autonomous flying capability, able to conduct autonomous flight route planning, all-round real-time imaging, real-time flight monitoring, two-way real-time communications, all-round environmental perception and autonomous return and landing. It is powered by a highly efficient and convenient charging system, leveraging XPeng’s supercharging technology.
The X2 has an user-friendly interface with one-key start, one-key return, and one-key landing, significantly reducing burdens for the user, delivering a safe and intelligent flight experience.
Before take-off, the system performs intelligent autonomous flight route planning based on the destination entered by the user, comprehensively evaluating factors such as surrounding buildings, no-fly and restricted areas, and weather conditions.
In a graphical recreational video, X2 demonstrates an efficient, effective and environmentally friendly commute from the top apron of a CBD building to a residential building, and connecting to the airport and other transportation hubs, simulating future lifestyle, business travel and other mobility scenarios.
In its first debut at an aerospace exhibition, X2 will be shown on September 28 at the 13th China International Aviation & Aerospace Exhibition (Airshow China 2021), showcasing its cutting-edge design and capabilities.
Introducing XPeng X2, the 5th generation flying vehicle
The XPeng X2 is the latest generation flying vehicle independently developed by HT Aero, having conducted more than 15,000 safe, manned flights. X2 is a pure electric two-seater enclosed-cockpit flying vehicle and an exploration of an aircraft-car integration with significantly improved effective load, passenger number, exterior design and flight control system than the previous generation.
X2 adopts a closed cockpit for the first time, with styling that shares the design language of the XPeng P7. It presents an elegant, minimalist and a teardrop profile. As well as its sci-fi appearance, X2 also takes into account high-efficiency aerodynamics to optimize flight performance.
With a full carbon fiber structure, X2 weighs 560 kilograms (empty aircraft with battery) and has the maximum take-off weight of 760 kilograms with a capacity of two passengers. It can cruise at a maximum design speed of 130 kilometers per hour and has a range of 35 minutes at a designed flying height of under 1,000 meters, suitable for low-altitude urban flight scenarios.
Powered purely by electricity, X2 has no carbon dioxide emissions during flight, in line with the company’s goal of green urban transportation. With 130 kilometers per hour, X2 can meet the needs of short-distance urban transportation, and can serve in scenarios such as air patrol, field rescue, and medical transportation.
About HT Aero
HT Aero aspires to be the leading pioneer of urban air mobility (UAM) and is dedicated to producing safe and intelligent electric flying vehicles which combine automotive and aerospace technologies to realize domestic air-travel usage at scale. Jointly funded and controlled by Mr. He Xiaopeng, XPeng Inc. and ZHAO Deli, HT Aero has a team of highly experienced R&D associates in multiple disciplines such as avionics, test flight, airworthiness, safety, structural mechanics, industrial design and embedded systems. Established in 2013, it has accumulated 15,000 safe, manned flight experiences. For more information, please visit https://www.aeroht.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923006034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom